Thrombotic thrombocytopenic purpura: Difference between revisions
From WikiMD's Wellness Encyclopedia
No edit summary |
CSV import |
||
| Line 1: | Line 1: | ||
{{SI}} | |||
{{Infobox medical condition | |||
| name = Thrombotic thrombocytopenic purpura | |||
| image = [[File:Echymosis.jpg|alt=Echymosis]] | |||
| caption = Echymosis, a common symptom of TTP | |||
| field = [[Hematology]] | |||
| synonyms = TTP | |||
| symptoms = [[Purpura]], [[petechiae]], [[anemia]], [[neurological symptoms]], [[renal failure]] | |||
| complications = [[Stroke]], [[myocardial infarction]], [[renal failure]] | |||
| onset = Sudden | |||
| duration = Variable | |||
| causes = [[ADAMTS13]] deficiency, [[autoimmune disease]], [[genetic mutation]] | |||
| risks = [[HIV]], [[pregnancy]], [[cancer]], [[chemotherapy]] | |||
| diagnosis = [[Blood test]], [[ADAMTS13 activity]], [[clinical presentation]] | |||
| differential = [[Hemolytic uremic syndrome]], [[immune thrombocytopenic purpura]], [[disseminated intravascular coagulation]] | |||
| treatment = [[Plasma exchange]], [[corticosteroids]], [[rituximab]] | |||
| prognosis = Variable, can be life-threatening | |||
| frequency = 3-4 cases per million per year | |||
| deaths = 10-20% with treatment | |||
}} | |||
Thrombotic thrombocytopenic purpura (TTP) is a rare and potentially life-threatening blood disorder characterized by the formation of small blood clots (thrombi) throughout the body. These blood clots can cause damage to organs and tissues and lead to a low platelet count (thrombocytopenia), which results in easy bruising and bleeding. | Thrombotic thrombocytopenic purpura (TTP) is a rare and potentially life-threatening blood disorder characterized by the formation of small blood clots (thrombi) throughout the body. These blood clots can cause damage to organs and tissues and lead to a low platelet count (thrombocytopenia), which results in easy bruising and bleeding. | ||
[[File:Thrombotic Thrombocytopenic Purpura (TTP).jpg|thumb|Thrombotic Thrombocytopenic Purpura (TTP)]] | [[File:Thrombotic Thrombocytopenic Purpura (TTP).jpg|left|thumb|Thrombotic Thrombocytopenic Purpura (TTP)]] | ||
==Causes and Pathophysiology== | ==Causes and Pathophysiology== | ||
*TTP is primarily caused by a deficiency or dysfunction of a specific enzyme called ADAMTS13 (a disintegrin and metalloproteinase with thrombospondin type 1 motif, member 13). ADAMTS13 is responsible for breaking down von Willebrand factor (vWF), a protein that helps with blood clotting. When ADAMTS13 is deficient or not functioning properly, there is an accumulation of large vWF multimers in the blood, leading to abnormal clot formation. | *TTP is primarily caused by a deficiency or dysfunction of a specific enzyme called ADAMTS13 (a disintegrin and metalloproteinase with thrombospondin type 1 motif, member 13). ADAMTS13 is responsible for breaking down von Willebrand factor (vWF), a protein that helps with blood clotting. When ADAMTS13 is deficient or not functioning properly, there is an accumulation of large vWF multimers in the blood, leading to abnormal clot formation. | ||
*In most cases, TTP is acquired, meaning it develops during a person's lifetime and is not inherited. Acquired TTP can be associated with the presence of autoantibodies that target and inhibit ADAMTS13 activity. These autoantibodies can be triggered by various factors, including infections, certain medications, autoimmune diseases, pregnancy, and cancer. | *In most cases, TTP is acquired, meaning it develops during a person's lifetime and is not inherited. Acquired TTP can be associated with the presence of autoantibodies that target and inhibit ADAMTS13 activity. These autoantibodies can be triggered by various factors, including infections, certain medications, autoimmune diseases, pregnancy, and cancer. | ||
==Signs and Symptoms== | ==Signs and Symptoms== | ||
* The classic pentad of TTP includes the following five features, although not all may be present in every case: | * The classic pentad of TTP includes the following five features, although not all may be present in every case: | ||
| Line 12: | Line 31: | ||
* '''Neurologic Symptoms''': TTP can affect the central nervous system and lead to symptoms such as confusion, headache, seizures, visual changes, and even coma. | * '''Neurologic Symptoms''': TTP can affect the central nervous system and lead to symptoms such as confusion, headache, seizures, visual changes, and even coma. | ||
* '''Renal Dysfunction''': Kidney involvement can occur in TTP, resulting in decreased urine output, kidney failure, and signs of kidney damage. | * '''Renal Dysfunction''': Kidney involvement can occur in TTP, resulting in decreased urine output, kidney failure, and signs of kidney damage. | ||
==Diagnosis and Treatment== | ==Diagnosis and Treatment== | ||
* The diagnosis of TTP is based on a combination of clinical features, blood tests, and specialized laboratory evaluations. Laboratory findings may include evidence of microangiopathic hemolytic anemia, thrombocytopenia, and an elevated lactate dehydrogenase (LDH) level. ADAMTS13 activity testing and the presence of ADAMTS13 autoantibodies can help confirm the diagnosis. | * The diagnosis of TTP is based on a combination of clinical features, blood tests, and specialized laboratory evaluations. Laboratory findings may include evidence of microangiopathic hemolytic anemia, thrombocytopenia, and an elevated lactate dehydrogenase (LDH) level. ADAMTS13 activity testing and the presence of ADAMTS13 autoantibodies can help confirm the diagnosis. | ||
* Immediate treatment is crucial in TTP to prevent complications and reduce mortality. The standard treatment approach involves plasma exchange (also known as plasmapheresis), which involves removing a patient's plasma and replacing it with fresh frozen plasma or a plasma substitute. Plasma exchange helps remove the autoantibodies and replenish ADAMTS13 activity. High-dose corticosteroids and immunosuppressive medications may also be administered to inhibit the formation of autoantibodies. | * Immediate treatment is crucial in TTP to prevent complications and reduce mortality. The standard treatment approach involves plasma exchange (also known as plasmapheresis), which involves removing a patient's plasma and replacing it with fresh frozen plasma or a plasma substitute. Plasma exchange helps remove the autoantibodies and replenish ADAMTS13 activity. High-dose corticosteroids and immunosuppressive medications may also be administered to inhibit the formation of autoantibodies. | ||
* In severe cases or when plasma exchange is not readily available, other treatments such as rituximab (a monoclonal antibody) or caplacizumab (a medication that blocks vWF) may be considered. Supportive care, including blood transfusions, close monitoring, and management of complications, is an important part of TTP treatment. | * In severe cases or when plasma exchange is not readily available, other treatments such as rituximab (a monoclonal antibody) or caplacizumab (a medication that blocks vWF) may be considered. Supportive care, including blood transfusions, close monitoring, and management of complications, is an important part of TTP treatment. | ||
==Prognosis== | ==Prognosis== | ||
With prompt diagnosis and appropriate treatment, the prognosis for TTP has improved significantly. However, TTP is still a serious condition that requires close medical management. Early intervention and ongoing monitoring are crucial to prevent relapses and manage potential long-term complications. | With prompt diagnosis and appropriate treatment, the prognosis for TTP has improved significantly. However, TTP is still a serious condition that requires close medical management. Early intervention and ongoing monitoring are crucial to prevent relapses and manage potential long-term complications. | ||
==Summary== | |||
== | |||
Thrombotic thrombocytopenic purpura (TTP) is a rare blood disorder characterized by the formation of blood clots throughout the body, leading to low platelet count and organ damage. It is primarily caused by a deficiency or dysfunction of the ADAMTS13 enzyme, which affects the breakdown of vWF. Prompt diagnosis and treatment, including plasma exchange and immunosuppressive medications, are essential in managing TTP and improving outcomes. | Thrombotic thrombocytopenic purpura (TTP) is a rare blood disorder characterized by the formation of blood clots throughout the body, leading to low platelet count and organ damage. It is primarily caused by a deficiency or dysfunction of the ADAMTS13 enzyme, which affects the breakdown of vWF. Prompt diagnosis and treatment, including plasma exchange and immunosuppressive medications, are essential in managing TTP and improving outcomes. | ||
==See Also== | ==See Also== | ||
* [[Hemolytic Anemia]] | * [[Hemolytic Anemia]] | ||
| Line 29: | Line 44: | ||
* [[Autoimmune Diseases]] | * [[Autoimmune Diseases]] | ||
* [[Plasma Exchange Therapy]] | * [[Plasma Exchange Therapy]] | ||
==References== | ==References== | ||
<references> | <references> | ||
Latest revision as of 19:29, 8 April 2025
Editor-In-Chief: Prab R Tumpati, MD
Obesity, Sleep & Internal medicine
Founder, WikiMD Wellnesspedia &
W8MD medical weight loss NYC and sleep center NYC
| Thrombotic thrombocytopenic purpura | |
|---|---|
| |
| Synonyms | TTP |
| Pronounce | N/A |
| Specialty | N/A |
| Symptoms | Purpura, petechiae, anemia, neurological symptoms, renal failure |
| Complications | Stroke, myocardial infarction, renal failure |
| Onset | Sudden |
| Duration | Variable |
| Types | N/A |
| Causes | ADAMTS13 deficiency, autoimmune disease, genetic mutation |
| Risks | HIV, pregnancy, cancer, chemotherapy |
| Diagnosis | Blood test, ADAMTS13 activity, clinical presentation |
| Differential diagnosis | Hemolytic uremic syndrome, immune thrombocytopenic purpura, disseminated intravascular coagulation |
| Prevention | N/A |
| Treatment | Plasma exchange, corticosteroids, rituximab |
| Medication | N/A |
| Prognosis | Variable, can be life-threatening |
| Frequency | 3-4 cases per million per year |
| Deaths | 10-20% with treatment |
Thrombotic thrombocytopenic purpura (TTP) is a rare and potentially life-threatening blood disorder characterized by the formation of small blood clots (thrombi) throughout the body. These blood clots can cause damage to organs and tissues and lead to a low platelet count (thrombocytopenia), which results in easy bruising and bleeding.
.jpg)
Causes and Pathophysiology[edit]
- TTP is primarily caused by a deficiency or dysfunction of a specific enzyme called ADAMTS13 (a disintegrin and metalloproteinase with thrombospondin type 1 motif, member 13). ADAMTS13 is responsible for breaking down von Willebrand factor (vWF), a protein that helps with blood clotting. When ADAMTS13 is deficient or not functioning properly, there is an accumulation of large vWF multimers in the blood, leading to abnormal clot formation.
- In most cases, TTP is acquired, meaning it develops during a person's lifetime and is not inherited. Acquired TTP can be associated with the presence of autoantibodies that target and inhibit ADAMTS13 activity. These autoantibodies can be triggered by various factors, including infections, certain medications, autoimmune diseases, pregnancy, and cancer.
Signs and Symptoms[edit]
- The classic pentad of TTP includes the following five features, although not all may be present in every case:
- Microangiopathic Hemolytic Anemia: This refers to the destruction of red blood cells as they pass through small blood vessels obstructed by blood clots. It can result in fatigue, weakness, pale skin, and jaundice.
- Thrombocytopenia: TTP leads to a low platelet count, which can cause easy bruising, petechiae (small red or purple spots on the skin), and excessive bleeding.
- Fever: Some individuals with TTP may experience fever, although it is not always present.
- Neurologic Symptoms: TTP can affect the central nervous system and lead to symptoms such as confusion, headache, seizures, visual changes, and even coma.
- Renal Dysfunction: Kidney involvement can occur in TTP, resulting in decreased urine output, kidney failure, and signs of kidney damage.
Diagnosis and Treatment[edit]
- The diagnosis of TTP is based on a combination of clinical features, blood tests, and specialized laboratory evaluations. Laboratory findings may include evidence of microangiopathic hemolytic anemia, thrombocytopenia, and an elevated lactate dehydrogenase (LDH) level. ADAMTS13 activity testing and the presence of ADAMTS13 autoantibodies can help confirm the diagnosis.
- Immediate treatment is crucial in TTP to prevent complications and reduce mortality. The standard treatment approach involves plasma exchange (also known as plasmapheresis), which involves removing a patient's plasma and replacing it with fresh frozen plasma or a plasma substitute. Plasma exchange helps remove the autoantibodies and replenish ADAMTS13 activity. High-dose corticosteroids and immunosuppressive medications may also be administered to inhibit the formation of autoantibodies.
- In severe cases or when plasma exchange is not readily available, other treatments such as rituximab (a monoclonal antibody) or caplacizumab (a medication that blocks vWF) may be considered. Supportive care, including blood transfusions, close monitoring, and management of complications, is an important part of TTP treatment.
Prognosis[edit]
With prompt diagnosis and appropriate treatment, the prognosis for TTP has improved significantly. However, TTP is still a serious condition that requires close medical management. Early intervention and ongoing monitoring are crucial to prevent relapses and manage potential long-term complications.
Summary[edit]
Thrombotic thrombocytopenic purpura (TTP) is a rare blood disorder characterized by the formation of blood clots throughout the body, leading to low platelet count and organ damage. It is primarily caused by a deficiency or dysfunction of the ADAMTS13 enzyme, which affects the breakdown of vWF. Prompt diagnosis and treatment, including plasma exchange and immunosuppressive medications, are essential in managing TTP and improving outcomes.
See Also[edit]
References[edit]
<references>
- Joly, Béatrice S., and Agnès Veyradier. "Understanding pathogenesis and therapy of thrombotic thrombocytopenic purpura." Journal of Thrombosis and Haemostasis 18, no. 12 (2020): 3121-3131.
- Scully, Marie, et al. "Thrombotic thrombocytopenic purpura and related thrombotic microangiopathies: diagnostic and therapeutic advances." Cancer Treatment and Research 177 (2019): 189-207.
- Peyvandi, Flora, et al. "Caplacizumab for Acquired Thrombotic Thrombocytopenic Purpura." New England Journal of Medicine 374, no. 6 (2016): 511-522.
</references>
